{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT06500026","nct_id":"NCT06500026","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06500026. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.","label":"BL-B01D1","type":"EXPERIMENTAL"},{"description":"Participants receive Topotecan as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.","label":"Topotecan","type":"EXPERIMENTAL"}],"collaborators":["Baili-Bio (Chengdu) Pharmaceutical Co., Ltd."],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Small Cell Lung Cancer"],"enrollment":{"count":722,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"BL-B01D1","type":"DRUG"},{"name":"Topotecan","type":"DRUG"}],"last_update":"2026-04-17","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","official_title":"A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS)","timeFrame":"Up to approximately 24 months"}],"references":[{"citation":"Zhao Y, Zhao H, Wang Q, Yang K, Li Y, Fu Z, Yang W, He Z, Wang Y, Ma Y, Yang Y, Fang W, Xiao S, Zhu H, Zhu Y, Zhang L, Huang Y. Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. J Clin Oncol. 2026 Jul 24:JCO2600243. doi: 10.1200/JCO-26-00243. Online ahead of print.","pmid":"42497381","type":"DERIVED"}],"start_date":{"date":"2024-08-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)","url":"https://clinicaltrials.gov/study/NCT06500026"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06500026"}